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ABBREVIATIONS 
• ARA – American Rheumatism Association 
• ANA – Antinuclear antibody 
• APLA – Antiphospholipid antibody 
• ANCA – Antinuclear cytoplasmic antibody 
• ACEI – Angiotensin converting enzyme inhibitor 
• ARB – Angiotensin II receptor blockers 
• CNS – Central nervous system 
• CIC – Circulating immune complex 
• C3,C4 – Complement factors 3,4 
• CTLA 4  - Cytotoxic T lymphocyte antigen 4 
• DRVT – Dilute Russell viper venom test 
• dsDNA – double stranded deoxy ribonucleic acid 
• EBV – Epstein Barr virus 
• ELISA – Enzyme linked immunosorbent assay 
• EM – Electron microscopy 
• GBM – Glomerular basement membrane 
• GN – Glomerulonephritis 
• HLA – Human leucocyte antigen 
• HIV – Human immunodeficiency virus 
• HBsAg – Hepatitis B surface antigen 
• HCV – Hepatitis C virus 
• IF – Immunofluorescence  
• IFN – Interferon 
• ISN/RPS – International society of nephrology/Renal pathology 
society 
• LM – Light microscopy 
• LN – Lupus nephritis 
• LFT – Liver function test 
• MMF – Mycophenolate mofetil 
• NIH – National institute of health 
• PGs – Prostaglandins 
• RFT – Renal function test 
• SLE – Systemic lupus erythematosus 
• Sm – Smith  
• TLR – Toll like receptor 
• UV light – Ultra violet light 
• USG - KUB – Ultrasonogram – Kidney ureter bladder 
• WHO – World health organisation 
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INTRODUCTION 
Systemic lupus erythematosus is an autoimmune disease of 
unknown etiology, characterized by the involvement of multiple organ 
systems 1. Organ damage is mediated by tissue binding autoantibodies 
and immune complexes. The hallmark of SLE is the presence of serum 
autoantibodies directed to nuclear constituents (i.e., antinuclear 
antibodies, ANA). In most of the patients, these autoantibodies are 
present for a few years before the first clinical symptoms appear 2. The 
clinical presentation and course of SLE are extremely variable. Some 
patients have spontaneous remissions; others may have mild 
musculoskeletal involvement which responds to therapy and a few die 
from progressive severe multisystem disease unresponsive to 
immunosuppressive therapy2
              Lupus nephritis is one of the common manifestations of SLE. 
Diagnosis of SLE is based on the 11 criteria defined by American 
Rheumatism Association (ARA). SLE patients develop wide range of 
autoantibodies 
. SLE commonly involves skin, joints, 
kidneys, serosal surfaces including pleura and pericardium, CNS and 
hematopoietic system. 
4,11,12,13. ANA is the most sensitive test for SLE and is 
present in more than 90% of patients but not specific for SLE. Anti 
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dsDNA is a more specific but less sensitive marker of SLE.  High titre of 
anti dsDNA correlates with disease activity and especially with lupus 
nephritis3, 4, 12, 14. Serum levels of complements C3 and C4 are usually 
decreased in active SLE and in active lupus nephritis 3, 4, 6, 7, 8, 9. Most of 
the patients with active proliferative lupus nephritis have high titre of anti 
dsDNA and low C3 and C4 levels.  
            Nowadays renal biopsy is recommended in almost all patients 
who have clinical or laboratory evidence of renal involvement to 
determine the histological class of lupus nephritis and thereby to plan 
therapy. But the requirement of renal biopsy has not been studied 
scientifically so far. So this study aimed to look at the need for renal 
biopsy in lupus nephritis scientifically90.  
            
                              
  
 3 
REVIEW OF LITERATURE 
     Lupus nephritis is a frequent and potentially life threatening 
complication of SLE 3,4,7,8,9,10. Almost 50 to 60% of patients with SLE 
have clinically significant renal involvement at the time of diagnosis. The 
diagnosis of SLE can be established by the presence of certain clinical 
and laboratory criteria defined by American Rheumatism Association 
(ARA).  
 
 Diagnostic Criteria for Systemic Lupus Erythematosus 
 
 Malar rash Fixed erythema, flat or raised, over the malar 
eminences 
Discoid rash Erythematous circular raised patches with adherent 
keratotic scaling and follicular plugging; atrophic 
scarring may occur 
Photosensitivity Exposure to ultraviolet light causes rash 
Oral ulcers Includes oral and nasopharyngeal ulcers, observed by 
physician 
Arthritis Nonerosive arthritis of two or more peripheral joints, 
with tenderness, swelling, or effusion 
Serositis Pleuritis or pericarditis documented by ECG or rub 
or evidence of effusion 
Renal disorder Proteinuria >0.5 g/day or 3+ on dipstick , or cellular 
casts 
Neurologic 
disorder 
Seizures or psychosis without other causes 
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Hematologic 
disorder 
Hemolytic anemia or leukopenia (<4000/µ𝐿𝐿) or 
lymphopenia (<1500/ µ𝐿𝐿) or 
thrombocytopenia(<100,000/ µ𝐿𝐿 ) in the absence of 
offending drugs 
Immunologic 
disorder 
Anti-dsDNA, anti-Sm, and/or anti-phospholipid 
antibodies 
Antinuclear 
antibodies 
An abnormal titer of ANA by immunofluorescence 
or an equivalent assay at any point in time in the 
absence of drugs known to induce ANAs 
 
 
Any four of 11 criteria over a life time gives 96% sensitivity and 
specificity for SLE. 
EPIDEMIOLOGY: 
           Women of child bearing age group between 15 and 45 years are 
more commonly affected. Female to male ratio is 10:1 3, 4, 5, 6. The gender 
predominance is less pronounced in children and elderly individuals. 
Incidence of renal disease is same in males and females. Lupus nephritis 
is more severe in children and males and is less likely in elderly 
individuals 5, 6, 8, 9. The overall incidence of SLE ranges from 1.8 to 7.6 
cases 1, 00,000 with a prevalence from 40 to 200 cases per 1, 00,000. 
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ETIOLOGY AND PATHOGENESIS OF SLE: 
          There is a complex interplay between genetic, environmental and 
hormonal factors with abnormal immune response results in 
autoimmunity in SLE. 
         Multiple genes predispose to SLE. This is supported by familial 
clustering of cases, concordance of SLE in identical twins (>25%) and the 
frequency of positive autoantibodies and autoimmune disorders in the 
family members of patients with SLE. Certain HLA genotypes (e.g., HLA 
B8, DR2 & DR3) and homogenous deficiency of certain complement 
factors, like C1q, C2, C4 and FCγR III polymorphisms carry a high risk 
of development of lupus 5,8,11. Genome wide association studies identified 
17 susceptible loci that involve genes associated with B cell signaling, 
Toll like receptors and neutrophil function 12
         Environmental factors like exposure to UV light (sun light), Epstein 
Barr virus, prolonged occupational exposure to silica dust and current 
smoking may also play a role in the onset of SLE
. 
2. UV light exposure can 
precipitate and exacerbate SLE and lupus nephritis possibly by increasing 
apoptosis in keratinocytes5,8. EBV antigens can mimic human antigen 
(antigen mimicry) and trigger SLE in susceptible individuals. Hormonal 
factors also play a role in SLE as evidenced by strong female 
preponderance and exacerbation of SLE with oestrogen containing oral 
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contraceptive pills and hormone replacement therapy. Estradiol binds to 
receptors in B & T lymphocytes, increasing activation and survival of 
these cells and thereby inducing prolonged immune responses and 
antibody production. 
        Abnormalities of immune regulation result in loss of self tolerance 
and subsequent autoimmune responses 4,5,6,15. Defective autoregulation of 
T cells, abnormal exposure to self antigen, self antigen driven T cell 
hyperactivity and polyclonal proliferation of B Cells due to increased B 
cell stimulating cytokines may contribute to production of autoantibodies 
4,13
 
. These autoantibodies are directed against nucleic acids, nucleosomes 
(DNA-histone complex), chromatin antigens and small nuclear and 
cytoplasmic ribonuclear proteins.  
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 Autoantibodies in Systemic Lupus Erythematosus (SLE) 
 
Antibody Prevalence, 
% 
Antigen 
Recognized 
Clinical Utility 
Antinuclear 
antibodies 
98 Multiple 
nuclear 
Best screening test; 
repeated negative tests 
make SLE unlikely 
Anti-dsDNA 70 DNA 
(double-
stranded) 
High titers are SLE-
specific and in some 
patients correlate with 
disease activity, 
nephritis, vasculitis 
Anti-Sm 25 Protein 
complexed to 
6 species of 
nuclear U1 
RNA 
Specific for SLE; no 
definite clinical 
correlations; most 
patients also have anti-
RNP; more common in 
blacks and Asians than 
whites 
Anti-RNP 40 Protein 
complexed to 
U1 RNA  
Not specific for SLE; 
high titers associated 
with syndromes that 
have overlap features 
of several rheumatic 
syndromes including 
SLE; more common in 
blacks than whites 
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Anti-Ro (SS-A) 30 Protein 
complexed to 
hY RNA, 
primarily 60 
kDa and 52 
kDa 
Not specific for SLE; 
associated with sicca 
syndrome, predisposes 
to subacute cutaneous 
lupus, and to neonatal 
lupus with congenital 
heart block; associated 
with decreased risk for 
nephritis 
Anti-La (SS-B) 10 47-kDa 
protein 
complexed to 
hY RNA 
Usually associated 
with anti-Ro; 
associated with 
decreased risk for 
nephritis 
Antihistone 70 Histones 
associated 
with DNA (in 
nucleosome, 
chromatin) 
More frequent in drug-
induced lupus than in 
SLE 
Antiphospholipid 50 Phospholipids, 
β2glycoprotein 
1 cofactor, 
prothrombin 
Three tests available—
ELISAs for cardiolipin 
and β2 glycoprotein 1, 
sensitive prothrombin 
time (DRVVT); 
predisposes to clotting, 
fetal loss, 
thrombocytopenia 
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Antierythrocyte 60 Erythrocyte 
membrane 
Measured as direct 
Coombs' test; a small 
proportion develops 
overt hemolysis 
Antiplatelet 30 Surface and 
altered 
cytoplasmic 
antigens on 
platelets 
Associated with 
thrombocytopenia but 
sensitivity and 
specificity are not good; 
this is not a useful 
clinical test 
Antineuronal 
(includes anti-
glutamate 
receptor) 
60 Neuronal and 
lymphocyte 
surface 
antigens 
In some series a 
positive test in CSF 
correlates with active 
CNS lupus. 
Antiribosomal P 20 Protein in 
ribosomes 
In some series a 
positive test in serum 
correlates with 
depression or psychosis 
due to CNS lupus 
 
 
Abnormal exposure to self antigen may occur through nuclear 
autoantigen clustering on the apoptotic blebs which may be associated 
with germ line mutation and leading on to expansion of autoreactive T 
cells. Spontaneous and inducible mouse animal models, like NZB B/W 
F1 hybrid, BxSB/yaa and MRL/lpr models showed that defective 
 10 
apoptosis may lead to defective clonal deletion of T cells and induce B 
cell proliferation8,11. 
In SLE, some autoantibodies are directly pathogenic, e.g., 
antibodies causing autoimmune hemolytic anemia. Others combine with 
antigen to produce immune complexes which deposit in various organs if 
they are not adequately cleared from the circulation8,22. Usually the 
complement components help in the clearance of immune complexes, but 
they also get activated and incorporated into the immune complexes and 
contribute to the inflammatory cascade and irreversible organ damage. 
PATHOGENESIS OF LUPUS NEPHRITIS: 
       In SLE, autoantibodies are produced against various  
antigens like dsDNA, Sm, RNA, Ro, La and histones14,19. Lupus nephritis 
has been considered as a human prototype of classical experimental 
immune complex mediated glomerulonephritis20. A hallmark of LN  
is the deposition of circulating immune complexes (CICs) and the  
in situ formation of others. Although the patients have autoantibodies 
against dsDNA, Sm antigen and C1q, the exact role of each antibody in 
the immune complex formation seen in glomerular disease remains 
unclear. 
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       The chronic deposition of CICs plays a major role in the mesangial 
and endocapillary patterns of LN. Size, charge and avidity of immune 
complexes, local hemodynamic factors and the clearing ability of the 
mesangium all influence the localization of CICs within the glomerulus21. 
In diffuse proliferative LN, the deposited immune complexes consist of 
nuclear antigens (e.g., DNA) and high affinity complement fixing IgG 
antibodies 6,20. In others, in situ immune complex formation in the 
subepithelial region is facilitated by binding of cationic nuclear antigens 
(histones) to anionic basement membrane proteins. Localization of 
immune complexes in the glomeruli leads to activation of complement 
cascade and complement mediated injury, activation of procoagulant 
factors, leukocyte infiltration with release of proteolytic enzymes and 
production of various cytokines regulating cellular proliferation and 
matrix synthesis. Glomerular damage may be potentiated by 
intraglomerular hypertension and activation of coagulation cascade 
especially in patients with antiphospholipid antibodies (APLA). Recent 
studies have shown that focal segmental necrotizing glomerular lesions 
without significant immune complex deposition, resembling a ‘pauci 
immune’ pattern with or without ANCAs, can occur in some SLE patients 
and cause glomerular and vascular damage23,24. 
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          APLAs directed against phospholipid-β2 glycoprotein complex 
produce endothelial and platelet dysfunction including reduced 
production of vasodilatory PGs like prostacycline and other anticoagulant 
factors, activation of plasminogen, inhibition of protein C or S and 
enhanced platelet aggregation can also potentiate glomerular and vascular 
lesions in SLE.  
PATHOLOGY OF LUPUS NEPHRITIS: 
            The histopathology of LN is extremely variable. Pleomorphic 
appearance of glomeruli in a single biopsy specimen is characteristic of 
LN3,9,20. Glomerular lesion can transform from one pattern to another 
spontaneously or after treatment. Previously the WHO classification was 
widely used for almost 30 years. Nowadays the ISN/RPS – 2003 based on 
LM, IF and electron microscopy findings, is widely used because it 
addressed many of the limitations of WHO classification27. Interobserver 
reproducibility and the predictive value have been improved with 
ISN/RPS system25, 26
 
.  
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 International Society of Nephrology / Renal Pathology  
classification of lupus nephritis (2003) 
 
 
CLASS 
 I 
  
MINIMAL MESANGIAL LUPUS NEPHRITIS 
Normal glomeruli by light microscopy, but mesangial 
immune deposits by immunofluorescence 
CLASS II MESANGIAL PROLIFERATIVE LUPUS 
NEPHRITIS 
  Purely mesangial hypercellularity of any degree or 
mesangial matrix expansion by light microscopy, with 
mesangial immune deposits 
  A few isolated subepithelial or subendothelial deposits 
may be visible by immunofluorescence or electron 
microscopy, but not by light microscopy 
CLASS III FOCAL LUPUS NEPHRITIS 
Active or inactive focal, segmental or global endo- or 
extracapillary glomerulonephritis involving <50% of all 
glomeruli, typically with focal subendothelial immune 
deposits, with or without mesangial alterations 
Class III 
(A) 
Active lesions: focal proliferative lupus nephritis 
Class III 
(A/C) 
Active and chronic lesions: focal proliferative and 
sclerosing lupus nephritis 
Class III 
(C) 
Chronic inactive lesions with glomerular scars: focal 
sclerosing lupus nephritis 
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CLASS IV DIFFUSE LUPUS NEPHRITIS 
 
Active or inactive diffuse, segmental or global endo- or 
extracapillary glomerulonephritis involving >50% of all 
glomeruli, typically with diffuse subendothelial 
immune deposits, with or without mesangial 
alterations. 
This class is divided into diffuse segmental (IV-S) 
lupus nephritis when >50% of the involved glomeruli 
have segmental lesions, and diffuse global (IV-G) lupus 
nephritis when >50% of the involved glomeruli have 
global lesions. Segmental is defined as a glomerular 
lesion that involves less than half of the glomerular tuft. 
This class includes cases with diffuse wire loop 
deposits but with little or no glomerular proliferation. 
Class IV-S 
(A) 
Active lesions: diffuse segmental proliferative lupus 
nephritis 
Class IV-G 
(A) 
Active lesions: diffuse global proliferative lupus 
nephritis 
Class IV-S 
(A/C) 
Active and chronic lesions: diffuse segmental 
proliferative and sclerosing lupus nephritis 
Class IV-G 
(A/C) 
Active and chronic lesions: diffuse global proliferative 
and sclerosing lupus nephritis 
Class IV-S 
(C) 
Chronic inactive lesions with scars: diffuse segmental 
sclerosing lupus nephritis 
Class IV-G 
(C) 
Chronic inactive lesions with scars: diffuse global 
sclerosing lupus nephritis 
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CLASS 
V 
MEMBRANOUS LUPUS NEPHRITIS 
 Global or segmental subepithelial immune deposits or their 
morphologic sequelae by light microscopy and by 
immunofluorescence or electron microscopy, with or 
without mesangial alterations 
 Lupus nephritis may occur in combination with class III or 
IV in which case both will be diagnosed 
Class V lupus nephritis may show advanced sclerosis 
CLASS 
VI 
ADVANCED SCLEROTIC LUPUS NEPHRITIS 
 ≥90% of glomeruli globally sclerosed without residual 
activity 
 
 
Class I – Minimal mesangial LN: 
              It denotes normal appearing glomeruli by LM but with minimal 
mesangial deposits on IF and EM. Even patients without any evidence of 
clinical renal disease often have minimal mesangial immune deposits on 
EM27
 
.  
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Class II – Mesangial proliferative LN: 
             It is characterized by pure mesangial hypercellularity (>3 cells in 
the mesangium distant from the vascular pole) on LM and mesangial 
immune deposits on IF and EM27. Rarely very minimal subendothelial 
and subepithelial deposits may be seen on IF or EM. 
Class III - Focal lupus nephritis:    
           It is defined as focal, segmental or global, endocapillary or 
extracapillary GN affecting less than 50% of the total glomeruli sampled. 
Focal endocapillary proliferation includes endothelial cells with 
infiltrating neutrophils and mononuclear cells27
 
.  
        This is subclassified into active proliferative (IIIA), inactive 
sclerosing (IIIC) and active & inactive (IIIA/C) lesions. Active lesions 
may show cellular crescents, fibrinoid necrosis, nuclear pyknosis or 
karyorrhexis and rupture of GBM. Hematoxylin bodies, denatured 
basophilic nuclear materials, are occasionally seen within the necrotizing 
lesions. Subendothelial immune deposits seen as ‘wire loop’ thickening 
of capillary walls or large intraluminal masses are known as hyaline 
thrombi. 
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Class IV – Diffuse LN: 
            It is characterized by proliferative changes as described in class III 
but involving >50% of the glomeruli27, 28, 29, 30
          It is characterized by regular subepithelial immune deposits 
producing membranous pattern
. This is also subclassified 
into diffuse segmental, class IV-S in which >50% of the affected 
glomeruli have segmental lesions and diffuse global, class IV-G in which 
>50% of the affected glomeruli have global lesions. These IV-S and IV-G 
lesions are again subclassified into IV-S (A, C, A/C) and IV-G (A, C, 
A/C) respectively according to the presence of active proliferating and 
inactive sclerosing lesions. 
          In general, extensive peripheral capillary wall subendothelial 
immune deposits and extracapillary proliferation (crescents) are common 
in class IV LN. GBM double contouring and focal necrotizing and 
crescentic lesions can occur in class IV as similar to those seen in small 
vessel vasculitides. 
Class V – Membranous LN:  
27, 31. The coexisting changes like 
mesangial hypercellularity and mesangial immune deposits in most of the 
cases help to distinguish membranous LN from primary membranous 
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nephropathy32. In early membranous nephropathy only subepithelial 
immune deposits are detected by IF/EM. Advanced well developed 
membranous LN lesions have typical diffuse thickening of the capillary 
walls with spikes. When these lesions are seen along with focal or diffuse 
endocapillary proliferative lesions and subendothelial immune deposits, 
they are classified as class V & III and class V & IV, respectively. 
Class VI – Advanced sclerosing LN: 
             It is defined by global glomerular sclerosis affecting >90% of the 
glomeruli. 
Tubulointerstitial disease, vascular lesions like vasculitis and TMA, and 
lupus podocytopathy are not included in ISN/RPS classification36, 37, 38, 39
 
.  
IMMUNOFLUORESCENCE STUDY: 
           In LN, immune deposits can be found in the glomeruli, tubules, 
interstitium and blood vessels. IgG is almost universal along with IgM 
and IgA in most of the biopsies; C3 and C1q are commonly present. The 
presence of IgG, IgM and IgA along with C3 and C1q is known as ‘full 
house’ staining and is highly suggestive of LN. Fibrin is often present in 
crescents and necrotizing lesions. 
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ELECTRON MICROSCOPY: 
           Distribution of immune deposits on EM corresponds to that of IF. 
Typically these deposits are electron dense and granular. Some have an 
organized ‘finger print’ like curvilinear microtubular or fibrillar structures 
composed of bands ranging from 10 to 15 nm in diameter. 
Tubuloreticular inclusions (IFN α foot prints) are intracellular branching 
tubular structures measuring 24 nm in diameter seen within the dilated 
cisternae of the endoplasmic reticulum of glomerular and vascular 
endothelial cells.  
PATHOLOGICAL INDICES OF ACTIVITY AND CHRONICITY: 
          A semiquantitative histologic scoring system (NIH system) has 
been developed based on the features of active (potential reversible 
lesions) and chronic (irreversible lesions) renal damage to predict the 
outcome of LN.  
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 Pathologic indices of activity and chronicity in lupus nephritis 
Chronicity 
index
Activity index
a 
b 
Glomerular 
sclerosis 
Cellular proliferation 
Fibrous crescents Fibrinoid necrosis, karyorrhexis 
Tubular atrophy Cellular crescents 
Interstitial 
fibrosis 
Hyaline thrombi, wire loop lesions 
  Leukocyte infiltration in glomerulus 
  Mononuclear-cell infiltration in interstitium 
 
aTo obtain a chronicity score, each parameter is graded 0 to 3 
depending on severity of involvement, and the grades are added. 
Glomerular sclerosis and fibrous crescents are graded as follows: 0, 
absent; 1+, <25% of glomeruli involved; 2+, 25% to 50% of 
glomeruli involved; 3+, >75% of glomeruli involved. Tubular 
atrophy and interstitial fibrosis are graded as follows: 0, absent; 1+, 
mild; 2+, moderate; 3+, severe. The maximum chronicity score is 12. 
bTo obtain an activity score, each parameter is graded 0 to 3 
depending on severity of involvement, and the individual grades are 
added. Fibrinoid necrosis and cellular crescents have been given a 
weighting factor of 2. The maximum activity score is 24. 
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          Austin and coworkers showed that both high activity index (>12) 
and high chronicity index (>4) are associated with poor 10 year renal 
survival rate33. A major value of calculating these indices is to compare 
the features in sequential biopsies and thereby efficacy of therapy and 
reversibility of the lesion can be assessed34, 35. 
SILENT LN / ANEPHRITIC NEPHRITIS: 
    It is an extremely uncommon form of LN characterized by active 
proliferative form of LN on biopsy but no clinical or urinary 
abnormalities suggestive of active disease and negative lupus serologies3
 
.  
CLINICAL MANIFESTATIONS: 
SPECTRUM OF RENAL SYNDROMES: 
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      Patients with class I lupus nephritis often have no evidence of clinical 
renal disease. Class II patients have mild or minimal clinical renal 
findings6, 28. They may have high anti dsDNA antibody titre or low 
complement levels, but the urinary sediment is inactive, hypertension is 
infrequent, proteinuria is usually less than 1g/day and the renal function is 
usually normal. Nephrotic proteinuria is extremely rare unless there is an 
evidence of lupus podocytopathy characterized by diffuse foot process 
effacement on EM 38, 39.  
         Class III patients often have hypertension, renal failure, proteinuria 
of >1g/day and active urinary sediments with positive lupus serologies. 
Nephrotic syndrome is seen in 20 to 30% of the patients at presentation. 
Patients with less extensive glomerular proliferation, fewer necrotizing 
features and no crescents are often normotensive and have preserved 
renal function.  
        Class IV LN is the most active and severe form of LN and is 
characterized by high anti dsDNA antibody titre, low complement levels 
and very active urinary sediments with RBCs and cellular casts30,40,41. It 
carries the worst renal prognosis. Nephrotic syndrome is seen in almost 
50% of the patients. Hypertension and renal failure are also more 
common.   
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        Nephrotic syndrome is the most common presentation of class V 
LN. Only about 60% of the patients will have elevated anti dsDNA 
antibody titre and low complement levels42. However hypertension and 
renal impairment may occur without any superimposed proliferative 
lesions. Renal vein thrombosis and pulmonary embolism can occur in 
patients with membranous LN24, 43.  
         Class VI, end stage LN results from ‘burnt out’ LN of long 
duration6. Almost all patients have hypertension and renal dysfunction.  
Anti dsDNA antibody titre and serum complement levels often normalize 
at this stage.  
SEROLOGICAL TESTS IN LUPUS: 
         ANA and anti dsDNA antibodies are included in the ARA criteria 
for diagnosing SLE and are commonly used to monitor the disease 
activity44. ANA is the most sensitive (>90%) screening test for SLE but 
not specific and it can be present in other rheumatological and non 
rheumatological disorders3, 4,5,20
       Anti dsDNA antibodies are more specific but less sensitive and are 
found in almost three fourths of the untreated SLE patients
. Neither the particular pattern of ANA on 
IF (homogenous, speckled, nucleolar or rim) nor the titre of ANA 
correlates well with the presence of severity of LN.  
44. These may 
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be detected by Farr radioimmunoassay, IF test directed against the DNA 
in the kinetoplast of Crithidia luciliae or by ELISA19, 44. High anti dsDNA 
antibody titre correlates well with clinical activity and flare of LN14, 44. 
        Anti Sm antibodies are very specific for SLE but are found only in 
25% of patients. AntiC1q antibodies also have been associated with 
activity of LN19, 44. Anti Ro/SSA and anti La/SSB antibodies are present 
in 25 to 30% and 5 to 15% of SLE patients, respectively. Maternal Anti 
Ro/SSA antibodies are important in the setting of neonatal lupus which is 
usually associated with cardiac conduction abnormalities in newborns45. 
Anti histone antibodies are present in >90% of patients with drug induced 
lupus46
       Serum levels of total hemolytic component (CH50) and complement 
components C3 and C4 are often decreased in patients with active SLE 
and active LN
.  
9, 44. Both C3 and C4 are depressed or the C4 alone is 
preferentially depressed in LN. Serial monitoring of complement levels, 
if declining, helps in predicting a flare in LN and normalization of 
depressed levels is often associated with improved renal outcome48. Low 
C4 and normal C3 reflect hereditary C4 deficiency49. One third to one 
half of the patients will have antiphospholipid antibodies (APLAs) 50, 51, 52. 
These are lupus anticoagulant and anticardiolipin antibodies. Lupus 
anticoagulant is best assessed by dilute Russell’s viper venom test 
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(DRVT). In SLE patients with pregnancy, presence of APLAs is 
associated with high fetal loss53. 
COURSE AND PROGNOSIS OF LN: 
         The course of LN is extremely varied with from <5% to >60% 
developing renal failure 29, 42,47,54,55. The natural course of LN is 
determined by the initial pattern and severity of renal involvement as 
modified by therapy, flares of disease activity and complications of 
treatment. In general, class I and II have excellent prognosis3, 47. Class III 
patients have extremely varied course. Those with mild proliferation 
respond well to therapy and only <5% progress to renal failure over 5 
years3, 4, 6,42,47,56. 
        Patients with more proliferation, necrotizing features or crescent 
formation have a prognosis similar to class IV LN. Those with diffuse 
proliferative LN have the least favorable prognosis in older series20, 29, 30, 
42. But nowadays the prognosis has markedly improved with modern 
immunosuppressive agents, with renal survival rate exceeding >90% at 5 
years in some series3, 30, 56, 57. The factors associated with progressive 
renal failure are old age, male sex, black race, anemia with hematocrit 
<26%, serum creatinine >2.4 mg/dl, high activity (>7) and chronicity (>3) 
on histopathology and the severity of tubulointerstitial damage40, 58, 59.  
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      Class V LN – Natural history is not clear and early studies showed 
better prognosis in membranous LN when compared to active 
proliferative lesions28. One U.S study found that 10 year survival rate was 
72% for pure membranous LN and only 20 to 48% for those having 
superimposed proliferative lesions (class III + V or class IV + V)31. But 
only Italian studies found the 10 year survival to be 93% for pure 
membranous LN60.  
TREATMENT OF LUPUS NEPHRITIS: 
          Patients with ISN/RPS classes I and II have an excellent prognosis 
and no specific therapy directed to the kidney. An exception to this is 
lupus podocytopathy which requires a short course of high dose 
corticosteroid therapy as in MCD 39
         Patients with class IV LN require combination therapy of 
corticosteroids and immunosuppressive agents
. Class III patients with mild 
proliferation respond well to a short course of high dose corticosteroids or 
a brief course of other immunosuppressive agents. Those with necrotizing 
features and crescents require aggressive therapy as in class IV LN. 
6, 30, 41, 47,56,61,62. Treatment 
is divided into induction and maintenance phases. Corticosteroids and 
intravenous cyclophosphamide65,66,67,68,69 or MMF37,38,39,40,41,42 are used in 
the induction phase to induce remission and azathioprine or MMF is used 
along with low dose prednisolone in the maintenance phase to avoid 
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relapse and disease flares in the future63,64. For the patients with combined 
class IV & V lesions, multitargeted regimen of tacrolimus, MMF and 
corticosteroids can be used76.  
BIOLOGICAL AGENTS IN LUPUS NEPHRITIS4, 77, 80, 81,164,167,168: 
1.  Rituximab (chimeric anti CD20 monoclonal antibody) 
2.  Abatacept (CTLA4 Ag) 
3.  Belimumab (B cell stimulating cytokine inhibitor) 
4.  Ocrelizumab (a fully humanized anti CD20 monoclonal antibody) 
5.  Epratuzumab (a humanized anti CD22 monoclonal antibody)   
6.  Eculizumab (anti C5a antibody) 
7.  Abetimus (prevents the anti dsDNA antibody formation) 
OTHER THERAPIES: 
       IV Ig and plasmapheresis may be useful in some patients. Total 
lymphoid irradiation, immunoablation by high dose cyclophosphamide 
and antilymphocyte globulin with or without reconstitution with 
autologous stem cells may be tried in resistant lupus78, 79
 
.  
 
 28 
MANAGEMENT OF MEMBRANOUS LN: 
       A short course of cyclosporine and low dose steroids along with ACE 
inhibitors or ARBs and statins can be used in patients with subnephrotic 
proteinuria and preserved renal function. For patients with nephrotic 
proteinuria and at higher risk for progressive renal disease, options 
include cyclosporine, MMF, azathioprine or i.v cyclophosphamide along 
with corticosteroids82. 
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AIMS & OBJECTIVES 
1. To evaluate the correlation between serological profile and 
histopathology of lupus nephritis.  
2. To find out the class of LN which has significant correlation with 
serological profile. 
3. To define the positive predictive value of anti dsDNA and low 
complement levels with proliferative lupus nephritis. 
4. To assess whether renal biopsy will alter the treatment plan in  
proliferative lupus nephritis. 
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MATERIALS AND METHODS 
Study design:  A prospective study 
Period of study: one year – Jan 2012 to Dec 2012 
Study setting: Nephrology Dept, Kilpauk medical college, Chennai. 
Ethical committee approval: obtained from ethical committee chairman, 
Kilpauk medical college. 
Consent: obtained informed consent including for renal biopsy. 
Subjects: All ANA positive female patients with evidence of renal 
involvement admitted in our dept. of Nephrology. 
 
Study criteria: 
Inclusion criteria:  
All ANA positive female SLE patients fulfilling ARA criteria between 15 
and 45 years of age group with any one of the following abnormalities- 
1. Proteinuria (spot urine PCR >0.5) 
2. Microscopic hematuria (≥ 3 RBCs/hpf) 
3. Increased serum creatinine (>1.2 but ≤ 1.8 mg/dl) 
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Exclusion criteria: 
1. Male SLE patients 
2. Patients below 15 and above 45 years of age group 
3. ANA negative lupus patients 
4. Serum creatinine >1.8 mg/dl 
Collaborating departments:  
1. Dept of Rheumatology 
2. Dept of Medicine 
3. Dept of Pathology 
4. Dept of Microbiology 
5. Dept of Biochemistry 
Study protocol: 
All the patients who fulfilled the study criteria were included in the study 
after getting informed consent for renal biopsy. A well designed proforma 
was used to collect the demographic and clinical details of the patients. 
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Investigations and methodologies: 
Apart from basic workup like urine analysis,CBC,RFT,LFT,ECG,X 
ray chest and USG KUB, the following other investigations have been 
done in all patients. 
1. Viral markers – HIV ELISA, HBsAg, antiHCV. 
2. Serological tests for SLE –  
• Anti dsDNA antibody – done by Immunofluorescence 
method using the DNA of the kinetoplast of Crithidia 
luciliae. 
• Serum complement levels for C3, C4 – by nephalometric 
method. 
• ANA has been done already before enrolling the patient into 
the study – by indirect immunofluorescence method using 
Hep 2 cells. 
• Percutaneous renal biopsy – specimen analysed by LM and 
IF. 
• Proteinuria was assessed by dipstick method. 
• Serum creatinine was measured by modified Jaffe’s kinetic 
method. 
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Statistical analysis: 
            Data analysis was done by using SPSS 17 software. Univariate 
analysis was done by chi square test. Multivariate analysis was done by 
logistic regression method.  
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                             RESULTS AND ANALYSIS 
In our study, 50 female SLE patients were included. 
1. Age distribution: 
                  Of 50 patients,25 (50%)were in the age group of 15 to 25 
years, 17 in 26 to 35 years and 8 were in 36 to 45 years.   
 
                                       Age distribution 
 
Age Frequency Percent 
15-25 25 50.0 
26-35 17 34.0 
36-45 8 16.0 
Total 50 100.0 
 
2. Proteinuria: 
                  All the 50 patients (100%) had proteinuria in our study. 
3. CLASS OF LN IN Renal biopsy: 
 
     35 patients (70%) had class IV lupus nephritis, 7 (14%) class II, 
4(8%) class V and 4 patients (8%) had class IV & V on renal 
biopsy. No one had class III LN in our study. Totally 39 patients 
(78%) had proliferative LN (class IV and class IV & V). 
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                                 Class of LN in Renal Biopsy 
 
Class Frequency Percent 
II 7 14.0 
IV 35 70.0 
V 4 8.0 
IV and V 4 8.0 
Total 50 100.0 
 
 
                       Proliferative LN - Classes IV,  IV & V 
 
 Frequency Percent 
Absent 11 22.0 
Present 39 78.0 
Total 50 100.0 
 
4. Microscopic hematuria and its correlation with the 
histopathology of LN: 
     
           Only 37 patients (74%) of LN had microscopic hematuria. 
29 of 35 patients (82.9%) with class IV, 3 of 4 patients (75%) with 
class IV&V, 2 of 7 patients (28.6%) with class II and 3 of 4 
patients (75%) with class V LN had microscopic hematuria. 32 of 
39 patients (82%) with proliferative LN had microscopic hematuria 
(P Value- 0.03).                                  
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                                    Microscopic hematuria 
 
 Frequency Percent 
Present 37 74.0 
Absent 13 26.0 
Total 50 100.0 
 
 
Class of LN & Microscopic hematuria - Correlation 
 
Renal 
Biopsy 
Microscopic 
hematuria 
Total 
 
 P  
Value 
 Present Absent   
 
 
 
 
 0.03 
II 
2 5 7 
28.6% 71.4.0% 100.0% 
IV 
29 6 35 
82.9% 17.1% 100.0% 
V 
3 1 4 
75.0% 25.0% 100.0% 
IV and V 
3 1 4 
75.0% 25.0% 100.0% 
Total 
37 13 50 
74.0% 26.0% 100.0% 
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5. Serum creatinine and its correlation with the histopathology of 
LN: 
       Only 17 of 50(34%) patients had increased serum creatinine. 
16 of 35(45.7%) patients with class IV, 1of 4(25%) patients with 
class V had ↑ed serum creatinine. None of the patients with class II 
and class IV& V had ↑ed serum creatinine (P Value- 0.047). 
                                         Serum creatinine 
 Frequency Percent 
Normal 33 66.0 
Increased 17 34.0 
Total 50 100.0 
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Class of LN & Serum creatinine - Correlation 
 
 
Renal 
Biopsy 
 
Serum creatinine Total p 
value Normal Increased 
II 
Count 7 0 7 
0.047 
% within Renal 
Biopsy 
100.0% 0% 100.0% 
IV 
Count 19 16 35 
% within Renal 
Biopsy 
54.3% 45.7% 100.0% 
V 
Count 3 1 4 
% within Renal 
Biopsy 
75.0% 25.0% 100.0% 
IV and V 
Count 4 0 4 
% within Renal 
Biopsy 
100.0% 0% 100.0% 
Total 
Count 33 17 50 
% within Renal 
Biopsy 
66.0% 34.0% 100.0% 
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6. Anti dsDNA and its correlation with the histopathology of LN: 
 
      Of 50 patients with LN, 41(82%) had anti dsDNA positivity. 34 of 35 
patients (97.1%) with class IV, all the 4 patients (100%) with class 
IV&V, 1 of 7 patients (14.3%) with class II and 2of 4 patients (50%) with 
class V LN had anti dsDNA positivity. Totally 38 of 39 patients (97.4%) 
with proliferative LN had anti dsDNA positivity (P Value < 0.001). 
                                             Anti dsDNA 
 
 Frequency Percent 
Negative 9 18.0 
Positive 41 82.0 
Total 50 100.0 
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Class of LN & Anti dsDNA - Correlation 
 
Renal 
Biopsy 
 
Anti dsDNA 
Total 
 P 
Value Negative Positive 
II Count 6 1 7  
 
 
 
 
 
 
 
<0.001 
% within Renal 
Biopsy 
85.7% 14.3% 100.0% 
IV Count 1 34 35 
% within Renal 
Biopsy 
2.9% 97.1% 100.0% 
V Count 2 2 4 
% within Renal 
Biopsy 
50.0% 50.0% 100.0% 
IV and V Count 0 4 4 
% within Renal 
Biopsy 
0% 100.0% 100.0% 
Total Count 9 41 50 
% within Renal 
Biopsy 
18.0% 82.0% 100.0% 
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Proliferative LN Classes IV, IV& V and Anti dsDNA- correlation 
 
 
Renal 
Biopsy – 
IV, IV & 
V 
 
Anti dsDNA 
Total 
 
P 
Value Negative Positive 
Absent 
Count 8 3 11  
 
 
 
<0.001 
% within 
Renal Biopsy 
- IV 
72.7% 27.3% 100.0% 
Present 
Count 1 38 39 
% within 
Renal Biopsy 
- IV 
2.6% 97.4% 100.0% 
Total 
Count 9 41 50 
% within 
Renal Biopsy 
- IV 
18.0% 82.0% 100.0% 
 
7. Serum C3 and its correlation with the histopathology of LN: 
     Of 50 patients with LN, 34(68%) had low C3 level in serum. 29 of 35 
patients (82.9%) with class IV, all the 4 patients (100%) with class IV&V 
and 1 of 4 patients (25%) with class V LN had low C3 level in serum. But 
none of the patients with class II LN had low C3 level. Totally 33 of 39 
patients (84.6%) with proliferative LN had low C3 level (P Value < 
0.001). 
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Serum C3 
 Frequency Percent 
 Normal 16 32.0 
 Decreased 34 68.0 
 Total 50 100.0 
 
Class of LN & serum C3 - correlation 
 
Renal 
Biopsy  
C3 
Total 
 
P Value Normal Decreased 
II Count 7 0 7  
 
 
 
 
 
 
<0.001 
 
 
 
 
 
% within Renal 
Biopsy 
100.0% 0% 100.0% 
IV Count 6 29 35 
% within Renal 
Biopsy 
17.1% 82.9% 100.0% 
V Count 3 1 4 
% within Renal 
Biopsy 
75.0% 25.0% 100.0% 
IV and 
V 
Count 0 4 4 
% within Renal 
Biopsy 
0% 100.0% 100.0% 
Total Count 16 34 50 
% within Renal 
Biopsy 
32.0% 68.0% 100.0% 
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      Proliferative LN Classes IV, IV& V and serum C3- correlation 
 
Renal Biopsy 
– IV, IV& V  
C3 
Total 
 
    P 
Value Normal Decreased 
Absent Count 10 1 11  
 
 
 
 
<0.001 
% within 
Renal Biopsy 
- IV 
90.9% 9.1% 100.0% 
Present Count 6 33 39 
% within 
Renal Biopsy 
– IV 
15.4% 84.6% 100.0% 
Total Count 16 34 50 
% within 
Renal Biopsy 
- IV 
32.0% 68.0% 100.0% 
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8. Serum C4 and its correlation with the histopathology of LN: 
      
          Of 50 patients with LN, 37(74%) had low C4 level in serum. 30 
of 35 patients (85.7%) with class IV, all the 4 patients (100%) with 
class IV&V and 3 of 4 patients (75%) with class V LN had low C4 
level in serum. But none of the patients with class II LN had low C4 
level. Totally 34 of 39 patients (87.2%) with proliferative LN had low 
C4 level (P Value < 0.001). 
                                                             
Serum C4 
 
 Frequency Percent 
 Normal 13 26.0 
Decreased 37 74.0 
Total 50 100.0 
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Class of LN & serum C4 - correlation 
 
Renal 
Biopsy  
C4 
Total 
P 
Value Normal Decreased 
II Count 7 0 7  
 
 
 
 
 
 
<0.001 
% within Renal 
Biopsy 
100.0% 0% 100.0% 
IV Count 5 30 35 
% within Renal 
Biopsy 
14.3% 85.7% 100.0% 
V Count 1 3 4 
% within Renal 
Biopsy 
25.0% 75.0% 100.0% 
IV and V Count 0 4 4 
% within Renal 
Biopsy 
0% 100.0% 100.0% 
Total Count 13 37 50 
% within Renal 
Biopsy 
26.0% 74.0% 100.0% 
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Proliferative LN Classes IV, IV& V and serum C4 - correlation 
 
 
Renal Biopsy – 
IV, IV&V  
C4 
Total 
P 
value Normal Decreased 
Absent Count 8 3 11  
 
 
 
<0.001 
% within Renal 
Biopsy - IV 
72.7% 27.3% 100.0% 
Present Count 5 34 39 
% within Renal 
Biopsy - IV 
12.8% 87.2% 100.0% 
Total      Count 13 37 50 
% within Renal 
Biopsy - IV 
26.0% 74.0% 100.0% 
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9. Logistic regression analysis: 
     
      It was used to analyze the correlation between all the three 
variables in serology (anti dsDNA positivity, low C3 and low C4) and 
proliferative form (class IV and class IV&V) of LN.  Positive 
predictive value of these variables was 97.4%. All the three variables, 
positive anti dsDNA, low C3 and low C4 independently predicted 
proliferative LN with significant P values, 0.029,0.030 and 0.049, 
respectively. 
 
Categorical Variables Coding 
 
 
Variables Comment Frequency 
C4 Normal 13 
Decreased 37 
C3 Normal 16 
Decreased 34 
Anti dsDNA Negative 9 
Positive 41 
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Classification Table 
 
Observed 
Predicted 
Renal Biopsy – 
IV Percentage 
Correct Absent Present 
Renal Biopsy - 
IV 
Absent 9 2 81.8 
Present 1 38 97.4 
Overall Percentage   94.0 
 
 
 
Variables in the Equation 
 
 B S.E. Wald df Sig. Exp(B) 
ANTI 
dsDNA(1) 
-3.985 1.829 4.744 1 .029 .019 
 C3(1) -3.126 1.444 4.688 1 .030 .044 
        
 C4(1) -2.952 1.518 3.783 1 .049 .052 
        
 Constant 5.028 1.522 10.921 1 .001 152.661 
 
. 
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   Of 39 patients with proliferative LN, 28(72%) had the combination 
of positive anti dsDNA, low C3 and low C4 levels in serum. But none of 
the patients with class II and class V LN had similar combination of 
serology. 
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                                             DISCUSSION 
           Most of the patients with active proliferative lupus nephritis have 
high titres of anti dsDNA and low serum complement levels 30, 40, 41.  
          We have studied 50 ANA positive female SLE patients with any 
one of the evidences of LN (proteinuria, microscopic hematuria or 
increased serum creatinine) to evaluate the correlation between 
serological profile and histopathology of LN.  
        Majority  (25 patients, 50%) were in the age group between 15 and 
25 years. All patients had significant proteinuria (>500 mg/day).  
      Masakki nakano et al, reported that 83.8% (31 of 37 pts) of patients 
had class IV LN on biopsy87. In our study, 70% (35 pts) had class IV and 
8% (4 pts) had combined class IV&V. Totally 78% (39 of 50 pts) had 
proliferative LN.  
     Elene Gonzalo, et al reported that 86.2% (50 of 58 pts) with 
proliferative LN had microscopic hematuria89
    Salwa Ibrahim and Ahmed Fayed reported renal impairment in 85% of 
the patients with LN
. In our study, 82% (32 of 
39 pts) of patients with proliferative LN had microscopic hematuria.  
88. In our study, it was 34% (17 of 50 pts). Masakki 
nakano et al, found that 67% (25 of 37 pts) of patients with proliferative 
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LN had renal insufficiency87. In our study, 41% (16 of 39 pts) of patients 
with proliferative LN had increased serum creatinine.  
   Vandana et al, reported high prevalence of antinucleosomal (88%) and 
anti dsDNA (80%) antibodies in SLE patients with active proliferative 
LN. But it was not statistically significant between LN group and non LN 
group (p >0.05)83. Cornelia Bigler et al, also reported high prevalence of 
anti dsDNA antibodies (94.3%) in SLE patients with active proliferative 
LN and it was statistically significant when compared to non LN group (p 
<0.001)84. Gonzalo et al reported that 84.5% (49 of 58 pts) with 
proliferative LN had anti dsDNA positivity 89. In our study, the 
prevalence of anti dsDNA was 97.1% in LN and 97.4% (38 of 39 pts) in 
proliferative LN (p <0.001).  
       In a study conducted by Carlos Franco et al, the prevalence of 
hypocomplementemia was 91.4% with class IV LN (p = 0.05)85. Gonzalo 
et al also reported high prevalence (91.2%) of hypocomplementemia with 
proliferative LN89
      Austin and Illei quoted that anti dsDNA was commonly absent with 
variable hypocomplementemia in membranous LN and anti dsDNA 
positivity with hypocomplementemia in proliferative LN
. In our study, C3 level was low in 68% of patients with 
LN and 84.6% with proliferative LN (p <0.001). C4 level was low in 74% 
of patients with LN and 87.2% with proliferative LN (p <0.001). 
86.  
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      In our study, 72%(28 of 39 pts) of the patients  with active 
proliferative LN(class IV, IV&V) had the combination of anti dsDNA 
positivity, low C3 and low C4 levels but none of the patients  with class II 
or class V LN had this combination of serology. All these three 
serological markers had significant correlation with proliferative LN 
(class IV, IV&V) and the positive predictive value was 97.4% (p<0.05).  
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                                       CONCLUSION 
• In our study, serological profile of SLE had significant correlation 
with histopathology of lupus nephritis.  
• Anti dsDNA, low C3 and low C4 had significant independent 
correlation (p<0.05) with proliferative LN (class IV, IV&V).  
• Positive predictive value of all these three serological markers put 
together for proliferative LN was 97.4%.  
• None of the patients with class II or class V LN had the 
combination of anti dsDNA positivity, low C3 and low C4 levels.  
• So, we may suggest that serology alone is sufficient to predict the 
proliferative LN and there can be a case for starting 
immunosuppressive therapy without biopsy in a known SLE 
patient with evidence of LN and positive serology. 
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                                                  PROFORMA 
          
Name:                                                                Age  :                                Sex  : 
 
Address: Phone No: 
 
History: 
 
 
Fever Joint pain/swelling Oral ulcer Skin rash Photosensitivity 
     
 
Pedal edema Facial puffiness Frothy urine  
   
 
Hypertension Diabetes mellitus Tuberculosis Seizures 
    
 
PIH Abortion IUD 
   
 
 
General examination   
 
Anemia:  Yes / No Malar rash:  Yes / No 
 
Jaundice:  Yes/ No Oral ulcer:  Yes / No 
 
Cyanosis:  Yes / No Arthritis:  Yes / No 
 
Clubbing:  Yes / No Purpuric spots:  Yes / No 
 
Lymphadenopathy:  Yes / No 
 
Pedal edema:  Yes / No 
 
 
Pulse rate: BP: 
 
Systemic examination 
 
CVS: Abdomen: 
 
 
RS: CNS: 
 
 
 
 
Investigations: 
 
1. Urine analysis:  
  
Protein Sugar Deposits 
   
 
2.  Spot Urine PCR: 
 
3.  Urine Culture and Sensitivity: 
 
4.  Complete Blood Count: 
 
Hb TC DC Platelets ESR 
     
 
5. Peripheral smear: 
 
6.  Blood investigations: 
 
Sugar Urea Creatinine 
   
 
Bilirubin SGOT SGPT ALP 
    
 
Proteins 
 
Total  Albumin Globulin 
   
 
7.  Viral markers: 
 
HIV HBsAg Anti HCV 
   
 
 
 
 
 
 
 
 
8.  Serological markers for SLE: 
 
ANA Anti dsDNA C3 C4 
    
 
9.  ECG: 
 
 
10.  X-ray chest: 
 
 
11.  USG KUB: 
 
 
12.  Renal Biopsy:  
 
                Light microscopy Immunofluorescence          Impression 
   
 
13.  Analysis of the study: 
 
1 AMUDHA 32 F P P ↑ POS POS ↓ N IV
2 GEETHA 20 F P P N POS POS ↓ ↓ IV
3 KALAIVANI 31 F P P N POS POS N N II
4 SELVI 27 F P P N POS POS ↓ ↓ IV  &  V
5 JAYANTHI 39 F P A N POS NEG N N II
6 ABINAYA SURIYA 15 F P P N POS POS ↓ N IV
7 GAYATHRI 21 F P P N POS POS ↓ N V
8 JAYA 35 F P A N POS NEG N N II
9 JAYANTHI 32 F P P N POS NEG N N II
10 SARITHA 22 F P P ↑ POS POS ↓ ↓ IV
11 SATHYA 23 F P P N POS POS ↓ ↓ IV
12 VALLIKANI 34 F P P ↑ POS POS ↓ N IV
13 SASI 18 F P P ↑ POS POS ↓ N IV
14 JOTHILAKSHMI 40 F P P N POS POS N ↓ V
15 VANITHA 37 F P P N POS POS N N IV
16 NASEEMA 45 F P P ↑ POS POS ↓ ↓ IV
17 REKHA 18 F P P N POS POS ↓ ↓ IV
18 SUMITHRA 27 F P A N POS POS ↓ ↓ IV
19 KASTHURI 21 F P P N POS POS ↓ ↓ IV
20 SELVI 40 F P A N POS NEG N ↓ V
21 PRABHAVATHI 25 F P P ↑ POS POS ↓ ↓ IV
22 PARIMALA 20 F P P N POS POS ↓ ↓ IV
23 SELVALAKSHMI 23 F P P N POS POS ↓ ↓ IV
24 REVATHI 31 F P A N POS POS ↓ ↓ IV
25 RAMAPRABHA 28 F P P N POS POS N ↓ IV
26 LATHA 33 F P P N POS POS N ↓ IV
PROTEINURIA  
PCR  > 0.5
 S.No            NAME   AGE    SEX
MICROSCOPIC 
HEMATURIA
    SERUM  
CREATININE
    ANA  Anti ds DNA   C3   C4
    RENAL BIOPSY   
ISN/RPS CLASS
27 RAMYA 16 F P P N POS POS ↓ ↓ IV
28 ANANTHI 28 F P P N POS POS ↓ ↓ IV
29 GNANASUNDARI 26 F P A N POS NEG N N II
30 SUDHA 29 F P A N POS POS ↓ ↓ IV  &  V
31 SASIKALA 24 F P A ↑ POS POS ↓ ↓ IV
32 MANICKAVALLI 17 F P P N POS POS ↓ ↓ IV  &  V
33 BANUMATHI 23 F P P ↑ POS POS ↓ ↓ IV
34 ANJALAI 38 F P P ↑ POS POS ↓ ↓ IV
35 ANITHA 25 F P A N POS NEG ↓ ↓ IV
36 BHAVANI 41 F P A N POS NEG N N II
37 HEMAMALINI 27 F P P ↑ POS POS ↓ ↓ IV
38 PUNITHAVALLI 32 F P P ↑ POS POS ↓ ↓ IV
39 YUVASRI 15 F P P ↑ POS POS ↓ ↓ IV
40 MEERA 15 F P P ↑ POS POS ↓ ↓ IV
41 GOKILA 28 F P P N POS POS N ↓ IV
42 KANIMOZHI 19 F P P N POS POS N ↓ IV
43 USHA 23 F P P ↑ POS POS ↓ ↓ IV
44 SUGANYA 19 F P A N POS POS ↓ ↓ IV
45 SARASWATHI 17 F P A N POS NEG N N II
46 VENMATHI 20 F P P N POS POS ↓ ↓ IV  &  V
47 BANGARAMMAL 35 F P P ↑ POS POS N ↓ IV
48 ANITHA 22 F P P ↑ POS NEG N ↓ V
49 PREETHA 15 F P A N POS POS ↓ ↓ IV
50 MARY ROSELINA 40 F P P ↑ POS POS ↓ ↓ IV
               P      - Present
POS  - Positive NEG - Negative
↓    -Decreased
N    - Normal F     - Female
A      - Absent
              ↑    - Increased

